NRP2 and cancer: In conclusion, miR-200 inhibits the activation of CAFs by targeting NRP2/VEGFR signaling, preventing CAFs from promoting cancer cell motility and invasiveness, reconstructing the ECM, recruiting macrophages and vascular endothelial cells, and facilitating angiogenesis.